Anavex Reports ANAVEX 2-73 Blocks Tau and Amyloid-Beta Proteins in a Preclinical Model of Alzheimer’s Disease

New York, NY — November 4, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) announces that issue 38 (2013) of the international scientific journal Neuropsychopharmacology contains a report demonstrating that ANAVEX 2-73 dose-dependently blocks Tau and amyloid-beta (“amyloid”) proteins and memory deficit in a mouse model of Alzheimer’s disease (AD). A reduction in…